Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions
暂无分享,去创建一个
[1] T. Honjo,et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.
[2] R. Abagyan,et al. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. , 1994, Journal of molecular biology.
[3] Ruben Abagyan,et al. ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..
[4] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[5] R Abagyan,et al. Flexible protein–ligand docking by global energy optimization in internal coordinates , 1997, Proteins.
[6] J. Bluestone,et al. Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.
[7] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.
[8] Ruben Abagyan,et al. Prediction of the binding energy for small molecules, peptides and proteins , 1999, Journal of molecular recognition : JMR.
[9] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[10] Yan Zhang,et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses , 2001, Nature.
[11] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[12] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[13] C. Drake. Basic overview of current immunotherapy approaches in urologic malignancy. , 2006, Urologic oncology.
[14] R. Eglen,et al. The Use of AlphaScreen Technology in HTS: Current Status , 2008, Current chemical genomics.
[15] Janice M Reichert,et al. Monoclonal antibodies as innovative therapeutics. , 2008, Current pharmaceutical biotechnology.
[16] Ruben Abagyan,et al. A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE) , 2008, J. Comput. Aided Mol. Des..
[17] Etienne Weiss,et al. Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.
[18] Ruben Abagyan,et al. Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. , 2009, Journal of medicinal chemistry.
[19] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[20] Abhinav A Shukla,et al. Recent advances in large-scale production of monoclonal antibodies and related proteins. , 2010, Trends in biotechnology.
[21] Louis M. Weiner,et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.
[22] Nan Wang,et al. Monoclonal antibodies in cancer therapy , 2011 .
[23] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[24] Ruben Abagyan,et al. Docking and scoring with ICM: the benchmarking results and strategies for improvement , 2012, Journal of Computer-Aided Molecular Design.
[25] F. Lyko,et al. Epigenetic cancer therapy: rationales, targets and drugs , 2012, Oncogene.
[26] A. Korman,et al. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates , 2014, Cancer Immunology Research.
[27] Yoshihiro Ito,et al. In vitro selection of a peptide aptamer that potentiates inhibition of cyclin-dependent kinase 2 by purvalanol , 2014 .
[28] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] K. Zak,et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) , 2016, Oncotarget.
[30] Axel Hoos,et al. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies , 2016, Nature Reviews Drug Discovery.
[31] Peptide-Assisted Enhancement of Inhibitory Effects of Small Molecular Inhibitors for Kinases , 2016 .
[32] C. Dann,et al. Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. , 2016, Journal of medicinal chemistry.
[33] P. Peddi,et al. Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment , 2016, OncoTargets and therapy.
[34] S. Sahasranaman,et al. Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy , 2016, Journal of clinical pharmacology.
[35] R. Ueda,et al. Current status of immunotherapy. , 2016, Japanese journal of clinical oncology.
[36] J. Pento. Monoclonal Antibodies for the Treatment of Cancer. , 2017, Anticancer research.
[37] S. Almo,et al. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy , 2017, EBioMedicine.
[38] G. Gao,et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab , 2017, Nature Communications.
[39] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[40] T. Holak,et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. , 2017, Journal of medicinal chemistry.
[41] L. Skalniak,et al. Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. , 2017, Angewandte Chemie.
[42] L. Skalniak,et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells , 2017, Oncotarget.
[43] P. Buchwald,et al. Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions. , 2018, Current topics in medicinal chemistry.
[44] Sultan Gulce-Iz,et al. Monoclonal antibodies in cancer immunotherapy , 2018, Molecular Biology Reports.
[45] Hongming Zhang,et al. Current status and future directions of cancer immunotherapy , 2018, Journal of Cancer.
[46] T. Holak,et al. CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not? , 2019, bioRxiv.
[47] M. Yamamura,et al. Enhancement of Binding Affinity of Folate to Its Receptor by Peptide Conjugation , 2019, International journal of molecular sciences.